Table 4. Summary of BMS-933043 Results in Preclinical Models of Schizophrenia.

Model	Impairment Approach	Active dose range (mg/kg)	Average plasma concentration range (subjects; time post-dose)
MK-801 set shifting	Acute NMDA deficit	1–10 (po)	50–1,860 nM (experimental; 150 min)
MK-801 Y maze	Acute NMDA deficit	1–10 (sc)	254–2,982 nM (experimental; 60 min)
S(+)Ketamine N40 gating	Acute NMDA deficit	0.56–3.0 (sc)	146–1,360 nM (satellite; 30 min)
Neonatal PCP ID/ED	Developmental	0.1–3.0 (po)	<3.07–225 nM (experimental; 150 min)
Neonatal PCP MMN	Developmental	0.03–3.0 (sc)	23–1,974 nM (satellite; 30 min)